Abstract: A measurement apparatus (800) to measure cortical thickness, the measurement apparatus may include at least one controller (810) which may be configured to: obtain magnetic resonance (MR) scan information of a region-of-interest of at least a portion of a cerebral cortex of a subject; form first, second and third meshes each comprising a plurality of points situated apart from each other, the first and third meshes being situated at inner and outer cortical boundary layers, respectively, of the cerebral cortex and the second mesh being situated between the first and third meshes; and/or for each of a plurality of points of the second mesh: determine a closest point of the first mesh and a closest point of the third mesh, determine a distance between the corresponding closest point of the first mesh and the corresponding closest point of the third mesh, said distance being corresponding with a cortical thickness.

Abstract: The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus, fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii. These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

Abstract: The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus, fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii. These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.